GSK Belgium vaccine unit faces job cuts; unions brace for announcement

GSK unions in Belgium expect 'bad news' on Wednesday regarding GSK Biologicals, the vaccine R&D and production entity, potentially involving job cuts. The company's Belgian workforce has already declined from over 9,000 to about 8,500. This signals restructuring in a key vaccine hub, with implications for GSK's operations and local employment.